Paper
0
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Authors
Conrad Cruz,Kenneth Micklethwaite
Barbara Savoldo,Carlos Ramos,Sharon Lam,Stephanie Ku,Oumar Diouf,Enli Liu,A. Barrett,Sawa Ito,Elizabeth Shpall,Robert Krance,Rammurti Kamble,George Carrum,Chitra Hosing,Adrian Gee,Zhuyong Mei,Bambi Grilley,Helen Heslop,Cliona Rooney,Malcolm Brenner,Catherine Bollard
+20 authors
,Gianpietro DottiJournal
Published
Sep 13, 2013
Show more
Save
Tip0
TipSave
Abstract
Key Points Allogeneic CD19-CAR VSTs are well tolerated by patients with relapsed B-cell malignancies post-HSCT. At periods of CD19-CAR VST persistence, these cells demonstrate antitumor activity.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.